Feasibility of a dose-adjusted fludarabine-melphalan conditioning prior autologous stem cell transplantation in a dialysis-dependent patient with mantle cell lymphoma

Annals of Hematology

Volumn 88, Issue 3, 2009, Pages 285-286

  Tendas, Andrea ^a   Cupelli, Luca ^a   Dentamaro, Teresa ^a   Scaramucci, Laura ^a   Palumbo, Roberto ^b   Niscola, Pasquale ^a   Giovannini, Marco ^a   Piccioni, Daniela ^a   Perrotti, Alessio Pio ^a   Fabritiis, Paolo ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b S EUGENIO HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; FLUDARABINE; ITRACONAZOLE; LEVOFLOXACIN; MELPHALAN; PIPERACILLIN PLUS TAZOBACTAM; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RITUXIMAB; TEICOPLANIN;

AGED; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER REGRESSION; CANCER RELAPSE; CASE REPORT; DIALYSIS; FEBRILE NEUTROPENIA; HEMODIALYSIS PATIENT; HUMAN; INFECTION PREVENTION; KARNOFSKY PERFORMANCE STATUS; KIDNEY FAILURE; LETTER; MALE; MANTLE CELL LYMPHOMA; MUCOSA INFLAMMATION; NEPHROTOXICITY; NEUTROPHIL COUNT; PRIORITY JOURNAL; PROGNOSIS; REDUCED INTENSITY CONDITIONING; SALVAGE THERAPY; STEM CELL MOBILIZATION; THROMBOCYTE COUNT;

AGED; COMBINED MODALITY THERAPY; DRUG THERAPY, COMBINATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LYMPHOMA, MANTLE-CELL; MALE; MELPHALAN; RENAL DIALYSIS; TRANSPLANTATION CONDITIONING; VIDARABINE;

EID: 59049093847     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00277-008-0578-5     Document Type: Letter

References (5)

1. Johnston LJ, Stockerl-Goldstein KE, Hu WW, Negrin RS, Hoppe RT, Blume KG et al (2000) Toxicity of high-dose sequential chemotherapy and purged autologous hematopoietic cell transplantation precludes its use in refractory/recurrent non-Hodgkin's lymphoma. Biol Blood Marrow Transplant 6(5A):555-562 doi: 10.1016/S1083-8791(00)70065-6
2. Devine SM, Sanborn R, Jessop E, Stock W, Huml M, Peace D et al (2001) Fludarabine and melphalan-based conditioning for patients with advanced hematological malignancies relapsing after a previous hematopoietic stem cell transplant. Bone Marrow Transplant 28(6):557-562 doi: 10.1038/ sj.bmt.1703198
3. Kielstein JT, Stadler M, Czock D, Keller F, Hertenstein B, Radermacher J (2005) Dialysate concentration and pharmacokinetics of 2F-Ara-A in a patient with acute renal failure. Eur J Haematol 74(6):533-534 doi: 10.1111/j.1600-0609.2005.00439.x
4. Lichtman SM, Etcubanas E, Budman DR, Eisenberg P, Zervos G, D'Amico P et al (2002) The pharmacokinetics and pharmacodynamics of fludarabine phosphate in patients with renal impairment: A prospective dose adjustment study. Cancer Invest 20(7-8):904-913 doi: 10.1081/ CNV-120005903
5. Pineda-Roman M, Tricot G (2007) High-dose therapy in patients with plasma cell dyscrasias and renal dysfunction. Contrib Nephrol 153:182-194 doi: 10.1159/000096767